The K-Ras ligand-Linker Conjugate 4 is primarily utilized in the field of targeted cancer therapy. It plays a crucial role in the development of drugs designed to specifically inhibit the K-Ras protein, which is often mutated in various cancers, including pancreatic, lung, and colorectal cancers. This conjugate is engineered to enhance the delivery and binding efficiency of therapeutic agents to the mutated K-Ras protein, thereby improving the precision of the treatment and reducing off-target effects. Its application is significant in the creation of more effective and personalized cancer therapies, offering hope for better management and outcomes for patients with K-Ras-driven malignancies.